Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.49 |
| ▸ | BID | P55957 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 8/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540032 | 0.85 | BCL2A1 (0.54) | CAPN1CTSBDPP3BCL2A1BID | |
| SCHEMBL30310982 | 0.82 | CCKBR (0.61) | DPP3BCHEGHSRCCKBR | |
| SCHEMBL13226652 | 0.81 | CAPN1 (0.54) | CAPN1CTSBDPP3CCKBRKISS1R | |
| SCHEMBL12890377 | 0.80 | TACR1 (0.51) | CAPN1CTSBDPP3BCHEGHSR | |
| SCHEMBL30310882 | 0.80 | CCKBR (0.61) | DPP3CCKBR | |
| SCHEMBL29539999 | 0.79 | BCL2A1 (0.71) | BCL2A1BIDTACR1 | |
| SCHEMBL24245857 | 0.79 | DPP3 (0.54) | CAPN1CTSBDPP3BCHEGHSR | |
| SCHEMBL23380930 | 0.79 | GHSR (0.57) | DPP3GHSRCCKBR | |
| SCHEMBL29454483 | 0.79 | DPP3 (0.57) | CAPN1CTSBDPP3 | |
| SCHEMBL29454493 | 0.79 | DPP3 (0.57) | CAPN1CTSBDPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CAPN1 1338/4885CTSB 159/4885DPP3 88/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CAPN1 1338/4885CTSB 159/4885DPP3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.